Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

If you think last week's decision by the federal government to halt $500 million in funding for vaccine development projects that use mRNA technology will only affect COVID vaccines, think again.

The United States is turning its back on what could be the greatest medical advance in a generation — vaccines made with messenger RNA, or mRNA, technology. The U.S. Department of Health and Human ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

The company, however, continues to work on a phase 1/2 study of its H5 mRNA flu vaccine for pandemic preparedness.

Earlier this month, Health Secretary Robert F. Kennedy Jr. announced he’s cutting nearly $500 million in funding for mRNA vaccine development from the Biomedical Advanced Research and Development ...

Dr. Sarah Boyd, an infectious disease specialist with Saint Luke's Health System, told KCUR that federal cuts to mRNA research and development could cause a setback in pandemic preparedness. Last week ...

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...

WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and ...

RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established ...

IBM and Moderna have achieved a groundbreaking milestone by simulating the longest mRNA pattern without the use of AI, instead leveraging the power of quantum computing. This collaboration marks a ...